SG11202103064YA - Antibody formulation - Google Patents
Antibody formulationInfo
- Publication number
- SG11202103064YA SG11202103064YA SG11202103064YA SG11202103064YA SG11202103064YA SG 11202103064Y A SG11202103064Y A SG 11202103064YA SG 11202103064Y A SG11202103064Y A SG 11202103064YA SG 11202103064Y A SG11202103064Y A SG 11202103064YA SG 11202103064Y A SG11202103064Y A SG 11202103064YA
- Authority
- SG
- Singapore
- Prior art keywords
- antibody formulation
- antibody
- formulation
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
- A61K39/39591—Stabilisation, fragmentation
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/02—Inorganic compounds
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/22—Heterocyclic compounds, e.g. ascorbic acid, tocopherol or pyrrolidones
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/08—Solutions
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/22—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against growth factors ; against growth regulators
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61M—DEVICES FOR INTRODUCING MEDIA INTO, OR ONTO, THE BODY; DEVICES FOR TRANSDUCING BODY MEDIA OR FOR TAKING MEDIA FROM THE BODY; DEVICES FOR PRODUCING OR ENDING SLEEP OR STUPOR
- A61M5/00—Devices for bringing media into the body in a subcutaneous, intra-vascular or intramuscular way; Accessories therefor, e.g. filling or cleaning devices, arm-rests
- A61M5/178—Syringes
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
- C07K2317/31—Immunoglobulins specific features characterized by aspects of specificity or valency multispecific
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/52—Constant or Fc region; Isotype
- C07K2317/526—CH3 domain
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
- C07K2317/565—Complementarity determining region [CDR]
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
- C07K2317/71—Decreased effector function due to an Fc-modification
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
- C07K2317/94—Stability, e.g. half-life, pH, temperature or enzyme-resistance
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Medicinal Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Veterinary Medicine (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- Pharmacology & Pharmacy (AREA)
- Organic Chemistry (AREA)
- Epidemiology (AREA)
- Immunology (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Biochemistry (AREA)
- Molecular Biology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Biophysics (AREA)
- Genetics & Genomics (AREA)
- Microbiology (AREA)
- Mycology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Oil, Petroleum & Natural Gas (AREA)
- Inorganic Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Peptides Or Proteins (AREA)
- Ophthalmology & Optometry (AREA)
- Dermatology (AREA)
- Medicinal Preparation (AREA)
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
EP18203104 | 2018-10-29 | ||
PCT/EP2019/079137 WO2020089051A1 (en) | 2018-10-29 | 2019-10-25 | Antibody formulation |
Publications (1)
Publication Number | Publication Date |
---|---|
SG11202103064YA true SG11202103064YA (en) | 2021-05-28 |
Family
ID=64082948
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
SG11202103064YA SG11202103064YA (en) | 2018-10-29 | 2019-10-25 | Antibody formulation |
Country Status (18)
Country | Link |
---|---|
US (1) | US20210324062A1 (en) |
EP (1) | EP3873519A1 (en) |
JP (1) | JP6920393B2 (en) |
KR (2) | KR102590359B1 (en) |
CN (1) | CN112930194A (en) |
AU (2) | AU2019370601B2 (en) |
BR (1) | BR112021007946A2 (en) |
CA (1) | CA3114728C (en) |
CL (1) | CL2021001037A1 (en) |
CR (1) | CR20210200A (en) |
IL (1) | IL281717A (en) |
MA (1) | MA54052A (en) |
MX (1) | MX2021004774A (en) |
MY (1) | MY195550A (en) |
PE (1) | PE20211865A1 (en) |
SG (1) | SG11202103064YA (en) |
TW (1) | TWI734233B (en) |
WO (1) | WO2020089051A1 (en) |
Families Citing this family (6)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
MA55033A (en) | 2019-02-18 | 2021-12-29 | Lilly Co Eli | THERAPEUTIC ANTIBODY FORMULATION |
PE20230986A1 (en) | 2020-09-04 | 2023-06-21 | Hoffmann La Roche | ANTIBODY THAT BINDS VEGF-A AND ANG2, AND METHODS OF USE |
CN116234574A (en) * | 2020-09-17 | 2023-06-06 | 江苏恒瑞医药股份有限公司 | Bispecific antigen binding molecules that specifically bind VEGF and ANG-2 |
CN115581765A (en) * | 2021-07-05 | 2023-01-10 | 山东新时代药业有限公司 | Recombinant humanized anti-BCMA/CD 3 bispecific antibody injection |
CN115569191A (en) * | 2021-07-05 | 2023-01-06 | 山东新时代药业有限公司 | Recombinant humanized anti-BCMA/CD 3 bispecific antibody freeze-dried preparation |
WO2024085606A1 (en) * | 2022-10-20 | 2024-04-25 | (주)니오테스바이오 | Bispecific antibody including first antigen-binding site that specifically binds to human angiopoietin-2, and use thereof |
Family Cites Families (31)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US5202238A (en) | 1987-10-27 | 1993-04-13 | Oncogen | Production of chimeric antibodies by homologous recombination |
US5204244A (en) | 1987-10-27 | 1993-04-20 | Oncogen | Production of chimeric antibodies by homologous recombination |
US5731168A (en) | 1995-03-01 | 1998-03-24 | Genentech, Inc. | Method for making heteromultimeric polypeptides |
CA2288600C (en) | 1997-05-02 | 2010-06-01 | Genentech, Inc. | A method for making multispecific antibodies having heteromultimeric and common components |
JO3000B1 (en) * | 2004-10-20 | 2016-09-05 | Genentech Inc | Antibody Formulations. |
ES2592271T3 (en) | 2005-03-31 | 2016-11-29 | Chugai Seiyaku Kabushiki Kaisha | Polypeptide production methods by regulating the association of polypeptides |
AR060070A1 (en) | 2006-03-24 | 2008-05-21 | Merck Patent Gmbh | HETERODYMERIC PROTEIN DOMAINS OBTAINED BY ENGINEERING |
WO2007147901A1 (en) | 2006-06-22 | 2007-12-27 | Novo Nordisk A/S | Production of bispecific antibodies |
US8242247B2 (en) | 2007-12-21 | 2012-08-14 | Hoffmann-La Roche Inc. | Bivalent, bispecific antibodies |
EP2235064B1 (en) | 2008-01-07 | 2015-11-25 | Amgen Inc. | Method for making antibody fc-heterodimeric molecules using electrostatic steering effects |
US8268314B2 (en) | 2008-10-08 | 2012-09-18 | Hoffmann-La Roche Inc. | Bispecific anti-VEGF/anti-ANG-2 antibodies |
EP2424567B1 (en) | 2009-04-27 | 2018-11-21 | OncoMed Pharmaceuticals, Inc. | Method for making heteromultimeric molecules |
AU2010343057B2 (en) | 2009-12-29 | 2017-02-23 | Aptevo Research And Development Llc | Heterodimer binding proteins and uses thereof |
AR080794A1 (en) | 2010-03-26 | 2012-05-09 | Hoffmann La Roche | BIVING SPECIFIC ANTIBODIES ANTI-VEGF / ANTI-ANG-2 |
TW201138821A (en) * | 2010-03-26 | 2011-11-16 | Roche Glycart Ag | Bispecific antibodies |
WO2011143545A1 (en) | 2010-05-14 | 2011-11-17 | Rinat Neuroscience Corporation | Heterodimeric proteins and methods for producing and purifying them |
BR112013011811A2 (en) | 2010-11-05 | 2023-02-23 | Zymeworks Inc | STABLE HETERODIMERIC ANTIBODY MODEL WITH MUTATIONS IN THE FC DOMAIN |
US9527925B2 (en) | 2011-04-01 | 2016-12-27 | Boehringer Ingelheim International Gmbh | Bispecific binding molecules binding to VEGF and ANG2 |
LT2794905T (en) | 2011-12-20 | 2020-07-10 | Medimmune, Llc | Modified polypeptides for bispecific antibody scaffolds |
KR102382304B1 (en) | 2012-04-20 | 2022-04-04 | 메뤼스 엔.페. | Methods and means for the production of ig-like molecules |
WO2014009465A1 (en) * | 2012-07-13 | 2014-01-16 | Roche Glycart Ag | Bispecific anti-vegf/anti-ang-2 antibodies and their use in the treatment of ocular vascular diseases |
KR20150063728A (en) | 2013-12-02 | 2015-06-10 | 삼성전자주식회사 | Anti-VEGF-C/anti-Ang2 bispecific antibody |
RU2698969C2 (en) * | 2014-01-15 | 2019-09-02 | Ф.Хоффманн-Ля Рош Аг | VARIANTS OF Fc-REGION WITH IMPROVED ABILITY TO BIND TO PROTEIN A |
TWI705827B (en) * | 2014-11-07 | 2020-10-01 | 瑞士商諾華公司 | Methods for treating ocular diseases |
US20180000932A1 (en) * | 2014-12-31 | 2018-01-04 | Novelmed Therapeutics, Inc. | Formulation of aglycosylated therapeutic antibodies |
KR101808234B1 (en) * | 2015-06-23 | 2017-12-12 | (주)알테오젠 | A stable liquid formulation of fusion protein with IgG Fc domain |
BR112018010005A2 (en) * | 2015-11-18 | 2018-11-21 | Formycon Ag | preloaded syringe and kit |
EP3407868A1 (en) * | 2016-01-26 | 2018-12-05 | Formycon AG | Liquid formulation of a vegf antagonist |
CN109310756B (en) | 2016-05-13 | 2022-06-28 | 奥美药业有限公司 | Novel angiopoietin 2, VEGF bispecific antagonists |
WO2018122053A1 (en) * | 2016-12-29 | 2018-07-05 | F. Hoffmann-La Roche Ag | Anti-angiopoietin-2 antibody formulation |
US11103552B2 (en) * | 2018-05-10 | 2021-08-31 | Regeneron Pharmaceuticals, Inc. | High concentration VEGF receptor fusion protein containing formulations |
-
2019
- 2019-10-25 MA MA054052A patent/MA54052A/en unknown
- 2019-10-25 MX MX2021004774A patent/MX2021004774A/en unknown
- 2019-10-25 KR KR1020227032627A patent/KR102590359B1/en active IP Right Grant
- 2019-10-25 CN CN201980071143.2A patent/CN112930194A/en active Pending
- 2019-10-25 AU AU2019370601A patent/AU2019370601B2/en active Active
- 2019-10-25 BR BR112021007946-7A patent/BR112021007946A2/en unknown
- 2019-10-25 SG SG11202103064YA patent/SG11202103064YA/en unknown
- 2019-10-25 PE PE2021000547A patent/PE20211865A1/en unknown
- 2019-10-25 KR KR1020217012818A patent/KR102467349B1/en active IP Right Grant
- 2019-10-25 CA CA3114728A patent/CA3114728C/en active Active
- 2019-10-25 WO PCT/EP2019/079137 patent/WO2020089051A1/en unknown
- 2019-10-25 EP EP19794983.7A patent/EP3873519A1/en active Pending
- 2019-10-25 MY MYPI2021002306A patent/MY195550A/en unknown
- 2019-10-25 CR CR20210200A patent/CR20210200A/en unknown
- 2019-10-28 TW TW108138766A patent/TWI734233B/en active
- 2019-10-28 JP JP2019195009A patent/JP6920393B2/en active Active
-
2021
- 2021-03-22 IL IL281717A patent/IL281717A/en unknown
- 2021-04-22 CL CL2021001037A patent/CL2021001037A1/en unknown
- 2021-04-28 US US17/242,667 patent/US20210324062A1/en active Pending
-
2024
- 2024-05-10 AU AU2024203126A patent/AU2024203126A1/en active Pending
Also Published As
Publication number | Publication date |
---|---|
KR20220136446A (en) | 2022-10-07 |
CL2021001037A1 (en) | 2021-09-24 |
TW202033180A (en) | 2020-09-16 |
JP6920393B2 (en) | 2021-08-18 |
MY195550A (en) | 2023-01-31 |
CA3114728C (en) | 2024-05-14 |
US20210324062A1 (en) | 2021-10-21 |
EP3873519A1 (en) | 2021-09-08 |
KR102467349B1 (en) | 2022-11-16 |
CR20210200A (en) | 2021-05-25 |
BR112021007946A2 (en) | 2021-08-03 |
KR102590359B1 (en) | 2023-10-16 |
KR20210069677A (en) | 2021-06-11 |
IL281717A (en) | 2021-05-31 |
CN112930194A (en) | 2021-06-08 |
AU2019370601A1 (en) | 2021-05-27 |
WO2020089051A1 (en) | 2020-05-07 |
TWI734233B (en) | 2021-07-21 |
JP2020097567A (en) | 2020-06-25 |
AU2019370601B2 (en) | 2024-05-23 |
AU2024203126A1 (en) | 2024-05-30 |
CA3114728A1 (en) | 2020-05-07 |
PE20211865A1 (en) | 2021-09-21 |
MA54052A (en) | 2022-02-09 |
MX2021004774A (en) | 2021-08-24 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
IL279321A (en) | Anti-sirpα antibody | |
IL269499A (en) | Stable antibody formulation | |
IL281717A (en) | Antibody formulation | |
IL282813A (en) | Antibody formulation | |
IL281255A (en) | Csf-1r antibody formulation | |
GB201801614D0 (en) | Formulation | |
GB201817867D0 (en) | Aerosolisable formulation | |
ZA202101177B (en) | Anti-btla antibody | |
IL282523A (en) | Aerosolisable formulation | |
IL271416A (en) | Bispecific antibody formulation | |
GB201811368D0 (en) | Antibody | |
IL281976A (en) | Anti-fgfr2 antibody formulations | |
GB201817859D0 (en) | Aerosolisable formulation | |
GB201816447D0 (en) | Formulation | |
ZA202006263B (en) | Antibody formulation | |
IL282461A (en) | Aerosolisable formulation | |
IL282392A (en) | Aerosolisable formulation | |
GB201817172D0 (en) | Antibody | |
IL283886A (en) | Antibody formulations | |
GB201817864D0 (en) | Aerosolisable formulation | |
GB201807312D0 (en) | Formulation | |
IL280138A (en) | Aerosolisable formulation | |
GB201813229D0 (en) | Formulation | |
ZA202006262B (en) | Stable antibody formulation | |
GB201813597D0 (en) | Antibody |